TABLE 3.
Main daily dose of oral corticosteroids (OCS) and inhaled corticosteroids (ICS) from dispensations reimbursed by the health insurance, among patients exposed to omalizumab, per time sequence from the year preceding omalizumab initiation (T0) to 2 years after T0
| Time sequence (months) | ||||||
| [−12;−6[ | [−6;T0[ | [T0;6[ | [6;12[ | [12;18[ | [18;24[ | |
| Patients within the time sequence # | ||||||
| Adults | 12 838 | 12 838 | 11 054 | 8510 | 7004 | 5820 |
| Children | 1964 | 1964 | 1782 | 1489 | 1262 | 1069 |
| Daily dose of ICS | ||||||
| Adults | ||||||
| Patients with ≥1 dispensations# | 10 630 (82.8) | 11 062 (86.2) | 9366 (84.7) | 7113 (83.6) | 5875 (83.9) | 4965 (85.3) |
| Daily dose (µg·day−1)¶ | 1391.0±1011.2 | 1507.7±1050.5 | 1575.1±1117.1 | 1489.6±1075.1 | 1467.9±1040.9 | 1451.4±1045.8 |
| Children | ||||||
| Patients with ≥1 dispensations# | 1675 (85.3) | 1754 (89.3) | 1556 (87.3) | 1252 (84.1) | 1037 (82.2) | 844 (79.0) |
| Daily dose (µg·day−1)¶ | 608.5±511.6 | 718.9±575.1 | 680.1±559.2 | 582.0±502.0 | 544.6±491.5 | 528.9±491.3 |
| Daily dose of OCS + | ||||||
| Adults | ||||||
| Patients with ≥1 dispensations# | 8604 (67.0) | 9673 (75.3) | 6554 (59.3) | 4750 (55.8) | 3778 (53.9) | 3161 (54.3) |
| Daily dose (mg·day−1)¶ | 7.6±7.4 | 9.0±8.1 | 8.6±8.8 | 7.3±7.4 | 7.3±7.4 | 7.0±7.1 |
Data are presented as n, n (%) or mean±sd. Daily dose corresponds to the sum of ICS or OCS doses dispensed over a time sequence, divided by the number of days in the time sequence. ICS dose has been converted to beclomethasone (chlorofluorocarbon)-equivalent, based on Global Initiative for Asthma 2019 [24], and OCS to prednisone-equivalent [25, 26]. #: subjects had to have a follow-up covering the entire time sequence to be accounted in a time sequence; ¶: among subjects with at least one dispensation; +: OCS mean daily dose is not given for children considering that OCS is not a continuous treatment for this population.